GlassScriptPhysician profile
Jami B Jenkins
NPI 1225161839
$1,069.51
in general payments reported to CMS, 2019-2025
22 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.87 · 2022: $148 · 2023: $224 · 2024: $264 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.62 | 2023-2025 | |
| Lilly USA, LLC | $160.77 | 2022-2025 | Zepbound |
| Novo Nordisk INC | $149.69 | 2022-2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $126.86 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $45.40 | 2022-2023 | Farxiga |
| Pfizer INC. | $40.46 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $40.29 | 2023-2024 | Spravato |
| Arbor Pharmaceuticals, INC. | $25.30 | 2021-2022 | |
| Sanofi Pasteur INC. | $23.16 | 2023 | |
| Exeltis, USA INC. | $23.03 | 2025 | Slynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.09 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $20.21 | 2025 | Recorlev |
| Merck Sharp & Dohme LLC | $18.60 | 2024 | Vaxelis, Gardasil, Gardasil 9 |
| Mayne Pharma Commercial LLC | $17.72 | 2023 | |
| Mylan Specialty L.P. | $17.52 | 2024 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $17.05 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.46 | 2025 | Eliquis |
| Vanda Pharmaceuticals INC. | $15.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.93 | 2024 | |
| Corcept Therapeutics | $13.65 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $13.50 | 2023 | Quviviq |
| Medtronic, INC. | $13.25 | 2023 | Minimed 770g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.